PRNewswire notes the existence of a securities class action against Capricor Therapeutics (NASDAQ: CAPR) alleging violations of Exchange Act §§10(b) and 20(a) and Rule 10b-5. No financial or operational figures are provided in the excerpt, but such litigation risk is a modest negative overhang for the stock.
PRNewswire notes the existence of a securities class action against Capricor Therapeutics (NASDAQ: CAPR) alleging violations of Exchange Act §§10(b) and 20(a) and Rule 10b-5. No financial or operational figures are provided in the excerpt, but such litigation risk is a modest negative overhang for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
